Impacto de la pandemia de COVID-19 en la resistencia antimicrobiana de Klebsiella pneumoniae y Acinetobacter baumannii en una unidad de cuidados intensivos

Autores/as

  • Gilberto Gambero Gaspar University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil https://orcid.org/0000-0002-6804-454X
  • Yasmim Saab Messias University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil https://orcid.org/0000-0001-9250-7535
  • Rodrigo de Carvalho Santana University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil https://orcid.org/0000-0002-5887-8663

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2026.235692

Palabras clave:

COVID-19, Bacterial resistance, Healthcare-associated infection

Resumen

Introducción: La pandemia de COVID-19 tuvo impactos significativos en la prevalencia de infecciones hospitalarias y en la resistencia antimicrobiana de patógenos críticos, como Klebsiella pneumoniae y Acinetobacter baumannii. Objetivos: Analizar los cambios en la sensibilidad de estos microorganismos y sus consecuencias para el control de infecciones hospitalarias. Métodos: Estudio de cohorte retrospectivo, dividido en período Pre-pandémico (1 de septiembre de 2018 al 28 de febrero de 2020) y período Pandémico (1 de marzo de 2020 al 31 de agosto de 2021), incluyendo pacientes adultos ingresados en la Unidad de Cuidados Intensivos. Se analizó la incidencia de Klebsiella pneumoniae y Acinetobacter baumannii, y sus respectivos perfiles de resistencia antimicrobiana, además de la densidad de incidencia de las Infecciones Asociadas a la Atención Sanitaria (IAAS), comparando ambos períodos. Resultados: Entre las infecciones, se observó un aumento en la densidad de incidencia únicamente de la Neumonía Asociada a la Ventilación Mecánica (NAVM). En cuanto a las bacterias de interés, hubo un aumento en la prevalencia de Klebsiella pneumoniae (de 8.2% a 21.9% de cultivos positivos/total de pacientes) y de Acinetobacter baumannii (de 7.5% a 21.7% de cultivos positivos/total de pacientes), junto con un cambio en el perfil de sensibilidad. Conclusión: A partir de los resultados, se puede inferir que hubo un impacto significativo de la pandemia de COVID-19 en la prevalencia y en el perfil de resistencia antimicrobiana de ambas bacterias estudiadas, junto con un aumento en los reportes de Neumonía Asociada a la Ventilación Mecánica.

Descargas

Los datos de descarga aún no están disponibles.

Biografía del autor/a

  • Gilberto Gambero Gaspar, University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil

    Professor Doutor

  • Yasmim Saab Messias, University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil

    Médica Assistente

  • Rodrigo de Carvalho Santana, University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil

    Professor Doutor

Referencias

1-SAMPAIO, J. L. M.; GALES, A. C. Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins. Brazilian Journal of Microbiology, v. 47, p. 31-37, 1 dez.2016.

2-ORGANIZAÇÃO MUNDIAL DA SAÚDE. Member States information session on infection prevention and control (IPC). Overview of the IPC situation Worldwide: highlights of achievement and gaps. Março 2022.

3-ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global report on infection and prevention control. OMS, 2022.

4- VINCENT, J.-L. Nosocomial infections in adult intensive-care units. The Lancet, v. 361, n. 9374, p. 2068-2077, jun. 2003.

5- KOLLEF, M.H. et al. Nosocomial infection. Critical care medicine, v. 49, n. 2, pg. 169-187, 14 jan. 2021.

6- VINCENT, J.-L., et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA, v. 302, n. 21, p. 2323, 2 dez. 2009.

7- VINCENT, J.-L., et al. Prevalence and outcomes of infections among patients in intensive care units in 2017. JAMA, v. 323, n. 15, p. 1478 - 1487, 21 abr. 2020.

8- SILVA, E. et al. Prevalência e desfechos clínicos de infecções em UTIs brasileiras: subanálise do estudo EPIC II. Revista Brasileira de Terapia Intensiva, v. 24, n. 2, p. 143-150, jun. 2012.

9- BRAGA, I. A. et al. Multi-hospital point prevalence study of healthcare-associated infections in 28 adult intensive care units in Brazil. Journal of Hospital Infection, v. 99, n. 3, p. 318–324, jul. 2018.

10- MAGILL, S. S. et al. Changes in Prevalence of Health Care- Associated Infections in U.S Hospitals. New England Journal of Medicine, v. 379, n. 18, p. 1732-1744, nov. 2018.

11-DESPOTOVIC, A. et al. Hospital acquired infections in the adult intensive care unit- Epidemiology, antimicrobial resistance patterns, and risk factors for acquisition and mortality. American Journal of Infection Control, v. 48, n. 10, p. 1211-1215, out. 2020.

12- Agência Nacional de Vigilância Sanitária. Programa Nacional de Prevenção e Controle de Infecções Relacionadas à Assistência à Saúde (PNPCIRAS) 2021 a 2025. ANVISA. Brasília, 05 mar. 2021.

13- Agência Nacional de Vigilância Sanitária. Critérios diagnósticos de infecções relacionadas à assistência à saúde. 1st ed. Brasília, Brasil: ANVISA; 2013.

14- SCHABERG, D. R.; CULVER, D.H.; GAYNES, R.P. Major trends in the microbial etiology of nosocomial infection. The American Journal of Medicine, v. 91, n. 3, p. S72-S75, set. 1991.

15- WEINSTEIN, R. A.; GAYNES R.; EDWARDS, J. R. Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clinical Infectious Diseases, v. 41, n. 6, p. 848-854, 15 set. 2005.

16- VINCENT, J. L. The Prevalence of Nosocomial Infection in Intensive Care Units in Europe.JAMA, v.274, n. 8, p. 634-644, 23 ago. 1995 Agosto, 1995.

17- MAGIORAKOS, A-P. et al. Multidrug-resistant, extensively drug resistant and pandrug-resistant bacteria: an international expert proposal of interim standard definitions of acquired resistance. Clinical Microbiology and Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, v. 18, n. 3, p. 268-81, 2012.

18- ANG, H.; SUN, X. Risk factors for multidrug-resistant gram-negative bacteria infection in intensive care units: A meta-analysis. International Journal of Nursing Practice, v. 24, n. 4, p. e12644, 25 mar. 2018.

19- ANDRADE, L.N.; COSTA DARINI, A.L. Beta-lactamase-producing gram-negative bacilli: which bla bla bla is this?. Journal of Infection Control, v. 6, n.1, p. 16-25, jan, 2017.

20- SADER,H. S. et al. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. Diagnostic Microbiology and Infectious Disease, v. 28, n. 2, p. 87-92, jun. 1997.

21- BUSH, K.; JACOBY, G. A. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy, v. 54, n. 3, p. 969-976, 7 dez. 2009.

22- HARRIS, P. N. A.; TMBYAH, P. A.; PATERSON, D. L. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? The Lancet Infectious Diseases, v. 15, n. 4, p. 475–485, abr. 2015.

23- JONES, R. N.; MARSHALL, S. A. Antimicrobial activity of cefepime tested against bush group I β-lactamase-producing strains resistant to ceftazidime a multilaboratory national and international clinical isolate study. Diagnostic Microbiology and Infectious Disease, v. 19, n. 1, p. 33-38, maio 1994.

24- MONTEIRO, J. et al. First Report of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil. Antimicrobial Agents and Chemotherapy, v. 53, n. 1, p. 333–334, jan. 2009.

25- NORDMANN, P.; POIREL, L. Emerging carbapenemases in Gram-negative aerobes. Clinical Microbiology and Infection, v. 8, n. 6, p. 321-331, jun. 2002.

26-SOUZA GUSATTI C. et al. First occurrence of bla OXA-58 in Acinetobacter baumannii isolated from clinical sample in Southern Brazil. Brazil Journal and Microbiology. v.43, n.1, p.243-246. Jan.2012.

27- GALES, A. C. et al. Emerging Importance of Multidrug-Resistant Acinetobacter Species and Stenotrophomonas maltophilas Pathogens in Seriously Ill Patients: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clinical Infectious Diseases, v. 32, n. s2, p. S104-S113, 15 maio 2001

28- PAGANO, M. et al. Comparative Analysis of Carbapenem-Resistant Acinetobacter baumannii Sequence Types in Southern Brazil: From the First Outbreak (2007-2008) to the Endemic Period (2013-2014). Microbial Drug Resistance, v.25, n.4, p.538-542, maio 2019

29- MARTINS, A. F. et al. High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil. American Journal of Infection Control, v. 40, n.2, p. 108-112, mar. 2012

30- DOI, Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, v.69, n.Supplement_7, p. S565-S575, 13 nov. 2019.

31- BORTOLLETI, F. et al. Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil. Emerging Infectious Diseases, v.22, n.10, p. 1849-1851, out. 2016.

32- LIMA, W. G. et al. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analyisis. European Journal of Clinical Microbiology & Infectious Diseases, v. 39, n. 8, p. 1427-1438, 12 jun.2020.

33- GENTELUCI, G. L. et al. Emergence of polymyxin B-resistant Acinetobacter baumannii in hospitals in Rio de Janeiro. Jornal Brasileiro de Patologia e Medicina Laboratorial, 2016.

34- PEREZ, L. R. R. et al. A four-year follow-up survey of antimicrobial resistance among Acinetobacter baumannii complex from inpatients in Southern Brazil. American Journal of Infection Control, v. 49, n.12, p.150-1505, dez.2021

35- ZHU, N. et al. A Novel Coronavirus from Patients with Pneumoniae in China, 2019. New England Journal of Medicine, v.382, n.8, 24 jan. 2020.

36- GUAN, W. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, v. 382, n. 18, 28 fev.2020.

37- RUUSKANEN, O. et al. Viral pneumonia. Lancet (London, England), v. 377, n. 9773, p. 1264-75, 2011.

38- RAWSON, T. M. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clinical Infectious Diseases, v. 71, n. 9, 2 maio 2020.

39- LANGFORD, B. J. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical Microbiology and Infection, jan. 2021.

40- GOYAL, P. et al. Clinical Characteristics of Covid-19 IN New York City. New England Journal of Medicine, 17 abr. 2020.

Descargas

Publicado

2026-11-18

Número

Sección

Artigo Original

Cómo citar

1.
Gaspar GG, Messias YS, Santana R de C. Impacto de la pandemia de COVID-19 en la resistencia antimicrobiana de Klebsiella pneumoniae y Acinetobacter baumannii en una unidad de cuidados intensivos. Medicina (Ribeirão Preto) [Internet]. 18 de noviembre de 2026 [citado 18 de noviembre de 2026];59(1):e-235692. Disponible en: https://revistas.usp.br/rmrp/article/view/235692